問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberU31402-277
NCT Number(ClinicalTrials.gov Identfier)-
Active

2024-03-01 - 2028-10-10

Phase II

Not yet recruiting4

Recruiting1

ICD-10C45.9

Mesothelioma, unspecified

ICD-10C79.9

Secondary malignant neoplasm of unspecified site

ICD-10C7A.00

Malignant carcinoid tumor of unspecified site

ICD-10C7A.094

Malignant carcinoid tumor of the foregut NOS

ICD-10C7A.095

Malignant carcinoid tumor of the midgut NOS

ICD-10C7A.096

Malignant carcinoid tumor of the hindgut NOS

ICD-10C7A.1

Malignant poorly differentiated neuroendocrine tumors

ICD-10C7A.8

Other malignant neuroendocrine tumors

ICD-10C7B.00

Secondary carcinoid tumors, unspecified site

ICD-10C80.1

Malignant (primary) neoplasm, unspecified

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9199.1

Malignant neoplasm of unspecified site (primary) (secondary)

-

  • Trial Applicant

     Daiichi Sankyo Taiwan Ltd. 

  • Sponsor

    -

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/05/16

Investigators and Locations

Principal Investigator Jen-Shi Chen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator 陳彥仰 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator Muh-Hwa Yang Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator Chia-Jui Yen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chia-Chi Lin

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Study Contacts

- -

Condition/Disease

-

Objectives

-

Test Drug

-

Active Ingredient

-

Dosage Form

-

Dosage

-

Endpoints

-

Inclution Criteria

-

Exclusion Criteria

-

The Estimated Number of Participants

  • Taiwan

    30 participants

  • Global

    640 participants